Study details
Enrolling now
TAS-102 Trial
M.D. Anderson Cancer Center
NCT IDNCT05343013ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
25
Study length
about 4.9 years
Ages
18+
Locations
1 site in TX
What this study is about
This trial is testing TAS-102, a medication, to measure ctDNA levels in colorectal cancer patients after 6 months of treatment. The goal is to determine the amount of ctDNA present in the blood.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take TAS-102
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: To determine the 6-month ctDNA clearance rate in colorectal cancer patients with minimal residual disease following 6 months of TAS-102 therapy.
Body systems
Oncology